PDCD1LG2 and non-small cell lung carcinoma: Cui et al. developed a comprehensive PET/CT radiomic model predicting pathological response after neoadjuvant toripalimab (PD-L1 and PD-L2) with chemotherapy in resectable stage III NSCLC patients [17].